{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:23:03Z","timestamp":1785284583727,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2141,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH"},{"name":"NIH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1093\/annonc\/mdt372","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T01:35:01Z","timestamp":1386293701000},"page":"16-23","source":"Crossref","is-referenced-by-count":40,"title":["Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses"],"prefix":"10.1016","volume":"25","author":[{"given":"J.P.A.","family":"Ioannidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Q.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Schully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt372_bb0010","first-page":"1","article-title":"Prescription drug use continues to increase: US prescription drug data for 2007\u20132008","volume":"42","author":"Gu","year":"2010","journal-title":"NCHS Data Brief"},{"key":"10.1093\/annonc\/mdt372_bb0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"10.1093\/annonc\/mdt372_bb0020","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/dc07-2308","article-title":"Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials","volume":"31","author":"Monami","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1093\/annonc\/mdt372_bb0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.diabet.2012.06.003","article-title":"Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis","volume":"38","author":"Colmers","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1093\/annonc\/mdt372_bb0030","doi-asserted-by":"crossref","first-page":"E675","DOI":"10.1503\/cmaj.112102","article-title":"Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis","volume":"184","author":"Colmers","year":"2012","journal-title":"CMAJ"},{"key":"10.1093\/annonc\/mdt372_bb0035","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00125-009-1568-4","article-title":"No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis","volume":"52","author":"Dejgaard","year":"2009","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdt372_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","article-title":"Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials","volume":"27","author":"Monami","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1093\/annonc\/mdt372_bb0045","first-page":"CD003697","article-title":"Statins and fibrates for preventing melanoma","author":"Dellavalle","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdt372_bb0050","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/jnci\/djj412","article-title":"Statins, fibrates, and melanoma risk: a systematic review and meta-analysis","volume":"98","author":"Freeman","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt372_bb0055","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/ijc.23550","article-title":"Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies","volume":"123","author":"Bonovas","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdt372_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcr158","article-title":"Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis","volume":"105","author":"Alberton","year":"2012","journal-title":"QJM"},{"key":"10.1093\/annonc\/mdt372_bb0065","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ejca.2008.06.025","article-title":"Statins and cancer: a systematic review and meta-analysis","volume":"44","author":"Kuoppala","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt372_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2007.02.073","article-title":"Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials","volume":"50","author":"Alsheikh-Ali","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdt372_bb0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2008.06.037","article-title":"Statins, low-density lipoprotein cholesterol, and risk of cancer","volume":"52","author":"Alsheikh-Ali","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdt372_bb0080","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt372_bb0085","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt372_bb0090","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(01)00705-7","article-title":"Do statins cause cancer? A meta-analysis of large randomized clinical trials","volume":"110","author":"Bjerre","year":"2001","journal-title":"Am J Med"},{"key":"10.1093\/annonc\/mdt372_bb0095","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1200\/JCO.2007.10.8936","article-title":"Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients","volume":"25","author":"Bonovas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt372_bb0100","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/j.1572-0241.2008.02051.x","article-title":"Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies","volume":"103","author":"Bonovas","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1093\/annonc\/mdt372_bb0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2125.2007.02959.x","article-title":"Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies","volume":"64","author":"Bonovas","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdt372_bb0110","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1200\/JCO.2005.02.7045","article-title":"Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies","volume":"23","author":"Bonovas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt372_bb0115","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1200\/JCO.2006.06.3560","article-title":"Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials","volume":"24","author":"Bonovas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt372_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10654-009-9396-x","article-title":"Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials","volume":"25","author":"Bonovas","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1093\/annonc\/mdt372_bb0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1503\/cmaj.060803","article-title":"Does pravastatin promote cancer in elderly patients? A meta-analysis","volume":"176","author":"Bonovas","year":"2007","journal-title":"CMAJ"},{"key":"10.1093\/annonc\/mdt372_bb0130","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ijc.22366","article-title":"Statins and risk of cancer: a systematic review and metaanalysis","volume":"120","author":"Browning","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdt372_bb0135","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdt372_bb0140","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10552-012-9979-9","article-title":"Statin use and risk of pancreatic cancer: a meta-analysis","volume":"23","author":"Cui","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1093\/annonc\/mdt372_bb0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt372_bb0150","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdt372_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdt372_bb0160","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/gerona\/62.8.879","article-title":"Efficacy and safety of statin monotherapy in older adults: a meta-analysis","volume":"62","author":"Roberts","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1093\/annonc\/mdt372_bb0165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ahj.2007.07.011","article-title":"The role of fibrates in the prevention of cardiovascular disease\u2014a pooled meta-analysis of long-term randomized placebo-controlled clinical trials","volume":"154","author":"Saha","year":"2007","journal-title":"Am Heart J"},{"key":"10.1093\/annonc\/mdt372_bb0170","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1742-1241.2006.01071.x","article-title":"Fluvastatin treatment is not associated with an increased incidence of cancer","volume":"60","author":"Stein","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1093\/annonc\/mdt372_bb0175","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdt372_bb0180","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt372_bb0185","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt372_bb0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt372_bb0195","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/j.1875-9114.1997.tb03084.x","article-title":"A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil","volume":"17","author":"Dong","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1093\/annonc\/mdt372_bb0200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.jhh.1000532","article-title":"Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis","volume":"11","author":"Ross","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1093\/annonc\/mdt372_bb0205","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","article-title":"Antihypertensive therapy and the risk of malignancies","volume":"22","author":"Grossman","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1093\/annonc\/mdt372_bb0210","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","article-title":"Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials","volume":"26","author":"Coleman","year":"2008","journal-title":"J Hypertens"},{"key":"10.1093\/annonc\/mdt372_bb0215","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","article-title":"Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk","volume":"108","author":"Sipahi","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1093\/annonc\/mdt372_bb0220","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","year":"2011","journal-title":"J Hypertens"},{"key":"10.1093\/annonc\/mdt372_bb0225","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt372_bb0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1093\/annonc\/mdt372_bb0235","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jaad.2005.10.053","article-title":"Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database","volume":"54","author":"Gottlieb","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdt372_bb0240","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdt372_bb0245","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdt372_bb0250","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1093\/annonc\/mdt372_bb0255","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2009.127225","article-title":"Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gaujoux-Viala","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdt372_bb0260","first-page":"CD008341","article-title":"Golimumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdt372_bb0265","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdt372_bb0270","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdt372_bb0275","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt372_bb0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdt372_bb0285","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10067-011-1895-y","article-title":"Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies","volume":"31","author":"Wong","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1093\/annonc\/mdt372_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1093\/annonc\/mdt372_bb0295","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1093\/annonc\/mdt372_bb0300","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdt372_bb0305","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2036.2005.02529.x","article-title":"Histamine receptor antagonists and incident colorectal adenomas","volume":"22","author":"Robertson","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1093\/annonc\/mdt372_bb0310","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/hrt.2008.161091","article-title":"Erythropoietin treatment in patients with chronic heart failure: a meta-analysis","volume":"95","author":"van der Meer","year":"2009","journal-title":"Heart"},{"key":"10.1093\/annonc\/mdt372_bb0315","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1191\/1352458502ms836oa","article-title":"A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis","volume":"8","author":"Ghalie","year":"2002","journal-title":"Mult Scler"},{"key":"10.1093\/annonc\/mdt372_bb0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12672-012-0112-z","article-title":"Systematic review and meta-analysis of insulin therapy and risk of cancer","volume":"3","author":"Janghorbani","year":"2012","journal-title":"Horm Cancer"},{"key":"10.1093\/annonc\/mdt372_bb0325","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10552-010-9686-3","article-title":"Diabetes and risk of pancreatic cancer: a pooled analysis of three large case\u2013control studies","volume":"22","author":"Li","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1093\/annonc\/mdt372_bb0330","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s10620-012-2055-1","article-title":"Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis","volume":"57","author":"Deng","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1093\/annonc\/mdt372_bb0335","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2337\/dc11-0512","article-title":"Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis","volume":"34","author":"Zhang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1093\/annonc\/mdt372_bb0340","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdt372_bb0345","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1093\/annonc\/mdt372_bb0350","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1634\/theoncologist.2011-0462","article-title":"Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis","volume":"17","author":"Soranna","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt372_bb0355","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CEJ.0b013e3282b721fe","article-title":"Statins and cancer: a meta-analysis of case-control studies","volume":"17","author":"Taylor","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"10.1093\/annonc\/mdt372_bb0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/157488607780598296","article-title":"Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis","volume":"2","author":"Corrao","year":"2007","journal-title":"Curr Drug Saf"},{"key":"10.1093\/annonc\/mdt372_bb0365","doi-asserted-by":"crossref","first-page":"E1073","DOI":"10.1503\/cmaj.101497","article-title":"Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies","volume":"183","author":"Yoon","year":"2011","journal-title":"CMAJ"},{"key":"10.1093\/annonc\/mdt372_bb0370","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bjo.2010.193987","article-title":"Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature","volume":"95","author":"Tressler","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1093\/annonc\/mdt372_bb0375","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdt372_bb0380","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.AOG.0000119226.39514.1d","article-title":"Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis","volume":"103","author":"Kashyap","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdt372_bb0385","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-010-1140-4","article-title":"Fertility drugs and the risk of breast cancer: a meta-analysis and review","volume":"124","author":"Zreik","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt372_bb0390","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1511\/2009.79.310","article-title":"Of beauty, sex and power","volume":"97","author":"Gelman","year":"2009","journal-title":"Am Scientist"},{"key":"10.1093\/annonc\/mdt372_bb0395","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/EDE.0b013e31818131e7","article-title":"Why most discovered true associations are inflated","volume":"19","author":"Ioannidis","year":"2008","journal-title":"Epidemiology"},{"key":"10.1093\/annonc\/mdt372_bb0400","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Med"},{"key":"10.1093\/annonc\/mdt372_bb0405","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMsa0806603","article-title":"Analyses of cancer data from three ezetimibe trials","volume":"359","author":"Peto","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt372_bb0410","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1002\/sim.5620","article-title":"Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership","volume":"31","author":"Ryan","year":"2012","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mdt372_bb0415","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1126\/science.3057627","article-title":"Scientific standards in epidemiologic studies of the menace of daily life","volume":"242","author":"Feinstein","year":"1988","journal-title":"Science"},{"key":"10.1093\/annonc\/mdt372_bb0420","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt372_bb0425","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bmj.322.7280.226","article-title":"Sifting the evidence-what's wrong with significance tests?","volume":"322","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdt372_bb0430","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jama.294.2.218","article-title":"Contradicted and initially stronger effects in highly cited clinical research","volume":"294","author":"Ioannidis","year":"2005","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt372_bb0435","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.286.7.821","article-title":"Comparison of evidence of treatment effects in randomized and nonrandomized studies","volume":"286","author":"Ioannidis","year":"2001","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt372_bb0440","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1503\/cmaj.050873","article-title":"Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies","volume":"174","author":"Papanikolaou","year":"2006","journal-title":"CMAJ"},{"key":"10.1093\/annonc\/mdt372_bb0445","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jama.2012.8144","article-title":"The importance of potential studies that have not existed and registration of observational data sets","volume":"308","author":"Ioannidis","year":"2012","journal-title":"JAMA"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/1\/16\/390258\/mdt372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:57:57Z","timestamp":1716253077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419359307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0923753419359307"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt372","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}